Novonesis Delivers Strong Full-year Results And Expects Continued Growth In 2025
26 February 2025, Denmark: In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at 36.1%.
Read More
26 February 2025, Denmark: In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at 36.1%.
Read MoreCheck Offers Available
